These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23275335)

  • 1. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
    So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
    J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
    Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
    Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
    Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
    Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
    Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
    Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI-3-Kinase P110α Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
    Montes-Casado M; Ojeda G; Criado G; Rojo JM; Portolés P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
    Foukas LC; Berenjeno IM; Gray A; Khwaja A; Vanhaesebroeck B
    Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11381-6. PubMed ID: 20534549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
    Yea SS; So L; Mallya S; Lee J; Rajasekaran K; Malarkannan S; Fruman DA
    PLoS One; 2014; 9(6):e99486. PubMed ID: 24915189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.
    Höland K; Boller D; Hagel C; Dolski S; Treszl A; Pardo OE; Cwiek P; Salm F; Leni Z; Shepherd PR; Styp-Rekowska B; Djonov V; von Bueren AO; Frei K; Arcaro A
    PLoS One; 2014; 9(4):e94132. PubMed ID: 24718026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 11. Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278).
    Acosta YY; Zafra MP; Ojeda G; Bernardone IS; Dianzani U; Portolés P; Rojo JM
    Cell Mol Life Sci; 2011 Sep; 68(18):3065-79. PubMed ID: 21188463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
    Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
    Front Immunol; 2018; 9():332. PubMed ID: 29535720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
    Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
    J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
    Bilancio A; Okkenhaug K; Camps M; Emery JL; Ruckle T; Rommel C; Vanhaesebroeck B
    Blood; 2006 Jan; 107(2):642-50. PubMed ID: 16179367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of P110α and P110δ catalytic subunits of PI3 kinase reverses impaired arterial healing after injury in hypercholesterolemic male mice.
    Chaudhuri P; Smith AH; Graham LM; Rosenbaum MA
    Am J Physiol Cell Physiol; 2021 Jun; 320(6):C943-C955. PubMed ID: 33689479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
    Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
    Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity.
    Buchanan CM; Dickson JM; Lee WJ; Guthridge MA; Kendall JD; Shepherd PR
    PLoS One; 2013; 8(8):e71337. PubMed ID: 23936502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells.
    Bekhite MM; Finkensieper A; Binas S; Müller J; Wetzker R; Figulla HR; Sauer H; Wartenberg M
    J Cell Sci; 2011 Jun; 124(Pt 11):1819-30. PubMed ID: 21540297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
    Soler A; Serra H; Pearce W; Angulo A; Guillermet-Guibert J; Friedman LS; Viñals F; Gerhardt H; Casanovas O; Graupera M; Vanhaesebroeck B
    J Exp Med; 2013 Sep; 210(10):1937-45. PubMed ID: 24043760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport.
    Li J; Song J; Cassidy MG; Rychahou P; Starr ME; Liu J; Li X; Epperly G; Weiss HL; Townsend CM; Gao T; Evers BM
    Mol Endocrinol; 2012 Aug; 26(8):1380-93. PubMed ID: 22700584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.